lornoxicam alone and with selegiline improves the neuroprotective effect and cognition in scopolamine induced neurodegeneration and cognitive impairment in rats

alzheimer is a progressive neurodegenerative disorder in which oxidative stress plays a major role. the present study was designed to investigate neuroprotective effect of lornoxicam, selegiline and co-administration of both drugs in scopolamine induced cognitive impairment and neurodegeneration. scopolamine (1.4mg/kg) was administered intraperitoniallyin male wistar rats. rectangular maze performance test was used to assess the memory performance test. various biochemical parameters such as catalase, 1, 1-diphenyl-2- picrylhydrazine (dpph), thiobarbituric acid reactive substances(tbars), reduced glutathione(gsh) and acetylcholine esterase (ache) were also assessed. intraperitonialscopolamine results marked memory impairment and oxidative damage. sub-acute treatment with lornoxicam (1.3mg/kg, p.o) and selegiline (0.49mg/kg, p.o) and co-administration of these two drugs for 8 days significantly attenuated scopolamine induced oxidative damage and neurodegeneration. besides, lornoxicam, selegiline and co-administration of both significantly reversed scopolamine administered increase in acetylcholine esterase activity. present study indicates protective effect of lornoxicam, selegiline and co-administration of both drugs against scopolamine induced cognitive impairment and oxidative damage. the memory enhancing capacity of the drugs was very significant when compared with disease control (p